Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
about
The pathogenesis of Niemann-Pick type C disease: a role for autophagy?Liver transplantation: immunosuppression and oncologyStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationIncidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosisProtein denaturation and protein:drugs interactions from intrinsic protein fluorescence measurements at the nanolitre scaleLow concentration of rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice.Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute StudyBiological agents in kidney transplantation: belatacept is entering the field.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.mTOR inhibitors in pediatric kidney transplantation.Antineoplastic effects of mammalian target of rapamycine inhibitors.Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation.Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.A case of esophageal adenocarcinoma on long-term rapamycin monotherapy.
P2860
Q24650767-ACC4AE13-68F9-412A-BA2B-5C07893395EFQ26827252-10E999A4-2201-4446-AC16-4E8EEC077A70Q27005375-83EC04A4-3D4F-4074-BB05-102BD5596ED4Q27025406-75B8D8B3-A5A7-45EB-8041-83C575434AD6Q34072745-EA2142B5-DEAA-4590-BD28-A96B2771B24CQ34498996-1FC7FE2A-6C5C-4CF4-B376-61224490C24BQ34557233-369B7A45-7D7C-4D96-AE92-B31BFDF524F1Q35818080-87A3EEB0-A37F-4012-ABFB-188A87697339Q37781355-0EB1406F-37CB-4DB0-8761-658FEEA0C937Q37937344-EFCD5E57-E0CA-4F59-959D-7EB9A1127E9AQ38112331-3B559081-FD24-48F7-BEA7-B321FEF8CFD3Q38156840-DA152712-7B6F-4799-98CB-A28C1EBA7DA7Q38533271-8E5BD97A-D4BD-48EC-90E9-EAFD782D85B0Q39067623-04648A42-F38B-4412-B220-F62F8395C17EQ41241688-066A387B-106A-4B77-9B23-DAEC21D65B6FQ43534252-C171CCB2-E19B-43D1-A064-D8712DC5F27EQ44110628-D1958B1C-B09D-45D2-B8A1-7EB70E501BF7Q44522008-E216FFAA-E9D5-476D-ABA0-59043ACCE9F6Q50446436-8CD9B122-A193-4A84-80B0-260C4AD948AE
P2860
Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunosuppression and tumor de ...... g dualistic role of rapamycin.
@en
Immunosuppression and tumor de ...... g dualistic role of rapamycin.
@nl
type
label
Immunosuppression and tumor de ...... g dualistic role of rapamycin.
@en
Immunosuppression and tumor de ...... g dualistic role of rapamycin.
@nl
prefLabel
Immunosuppression and tumor de ...... g dualistic role of rapamycin.
@en
Immunosuppression and tumor de ...... g dualistic role of rapamycin.
@nl
P2093
P2860
P1476
Immunosuppression and tumor de ...... g dualistic role of rapamycin.
@en
P2093
Andreas Gaumann
Edward K Geissler
Hans J Schlitt
P2860
P304
P356
10.1111/J.1432-2277.2007.00610.X
P577
2007-12-05T00:00:00Z